These easily digestible, informative briefings provide insight on a key topic impacting the health insurance sector right now and into the future. These briefings also offer advice for members on how to begin identifying strategies and a plan of action to best position and prepare themselves in the light of new challenges and opportunities. Set aside 5 minutes to bring yourself up to speed.

Glucagon-like peptide-1 receptor agonists (GLP-1s) were first introduced in 2005 with the FDA approval of exenatide (Byetta) for the treatment of type 2 diabetes. They have offered an effective option for patients for two decades now and have seen increasing use  in weight management. This effectiveness in lowering blood sugar levels and supporting weight loss has led to a growth in demand in recent years. However, with rising costs, expanding off-label use, and increasing prescriptions, these drugs present both opportunities and challenges for private health insurers.